erlotinib hydrochloride has been researched along with Response Evaluation Criteria in Solid Tumors in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (81.82) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Alonso Garcia, M; Fabre, E; Frimodt-Moller, B; Garon, EB; Moro-Sibilot, D; Nadal, E; Nakagawa, K; Novello, S; Ponce Aix, S; Reck, M; Visseren-Grul, CM; Zimmermann, AH | 1 |
| Dong, Y; Li, D; Li, Q; Miao, Q | 1 |
| Aix, SP; Barlesi, F; Bidoli, P; Camps, C; Carcereny, E; Coate, L; Cuffe, S; Curioni-Fontecedro, A; Dafni, U; Favaretto, A; Felip, E; Froesch, P; Früh, M; Gautschi, O; Gómez-Codina, J; Hanrahan, E; Kammler, R; Karachaliou, N; Kassapian, M; Kotsakis, A; Majem, M; Massutí, B; Molina-Vila, MA; Palmero, R; Peters, S; Pless, M; Popat, S; Porta, R; Puente, J; Rabaglio, M; Rauch, D; Reguart, N; Rosell, R; Ruepp, B; Shah, R; Shames, DS; Stahel, RA; Tam, R; Thomas, M | 1 |
| Du, D; Fang, M; Song, T; Wu, S; Zhang, X | 1 |
| Ahn, L; Arbour, KC; Beal, K; Daras, M; Hayes, SA; Kris, MG; Ni, A; Pao, W; Riely, GJ; Rodriguez, CR; Young, RJ; Yu, HA | 1 |
| Glisson, BS; Gold, KA; Johnson, FM; Kies, MS; Lee, JJ; William, WN | 1 |
| Baik, C; Baker, KK; Chow, LQ; Eaton, K; Goulart, BH; Guerriero, MK; Lee, S; Martins, RG; Redman, MW; Rodriguez, CP; Santana-Davila, R | 1 |
| Chung, JH; Jheon, S; Jin, Y; Kim, H; Kim, JE; Kim, K; Lee, CT; Sun, PL; Yoo, SB | 1 |
| Ahn, MJ; Button, P; Chan, KC; Kang, JH; Kim, SW; Lee, JS; Lin, MC; Mok, T; Park, K; Perez-Moreno, P; Sriuranpong, V; Tsai, CM; Yu, CJ | 1 |
| Chang, JW; Cheng, NM; Chung, HW; Fang, YD; Ho, KC; Hou, MM; Liu, YC; Su, TP; Yang, CT; Yen, TC | 1 |
| He, X; Hong, S; Huang, Y; Ma, Y; Sheng, J; Yang, Y; Zhang, J; Zhang, L; Zhang, Y; Zhang, Z; Zhao, H; Zhou, T | 1 |
1 review(s) available for erlotinib hydrochloride and Response Evaluation Criteria in Solid Tumors
| Article | Year |
|---|---|
Erlotinib as a salvage treatment after gefitinib failure for advanced non-small-cell lung cancer patients with brain metastasis: A successful case report and review.
Topics: Biopsy; Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Drug Resistance, Neoplasm; Drug Substitution; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Progression-Free Survival; Radiotherapy, Intensity-Modulated; Response Evaluation Criteria in Solid Tumors; Salvage Therapy | 2021 |
5 trial(s) available for erlotinib hydrochloride and Response Evaluation Criteria in Solid Tumors
| Article | Year |
|---|---|
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Europe; Female; Humans; Hypertension; Lung Neoplasms; Male; Middle Aged; Mutation; Placebos; Progression-Free Survival; Ramucirumab; Response Evaluation Criteria in Solid Tumors; Survival Rate; United States; Young Adult | 2021 |
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Intention to Treat Analysis; International Cooperation; Lung Neoplasms; Male; Middle Aged; Mutation; Proof of Concept Study; Response Evaluation Criteria in Solid Tumors | 2017 |
Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase 2 clinical trial.
Topics: Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Response Evaluation Criteria in Solid Tumors; Skin Neoplasms | 2018 |
Racial disparity in oncologic and quality-of-life outcomes in patients with locally advanced head and neck squamous cell carcinomas enrolled in a randomized phase 2 trial.
Topics: Adult; Aged; Antineoplastic Agents; Chemoradiotherapy; Cisplatin; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Health Status Disparities; Humans; Male; Middle Aged; Quality of Life; Racial Groups; Response Evaluation Criteria in Solid Tumors; Squamous Cell Carcinoma of Head and Neck; Survival Analysis | 2018 |
First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Response Evaluation Criteria in Solid Tumors | 2016 |
5 other study(ies) available for erlotinib hydrochloride and Response Evaluation Criteria in Solid Tumors
| Article | Year |
|---|---|
Comparative study of radiotherapy plus erlotinib versus chemoradiotherapy for elderly patients with esophageal cancer: a propensity score-matched analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Erlotinib Hydrochloride; Esophageal Neoplasms; Female; Hematologic Diseases; Humans; Male; Neoplasm Staging; Paclitaxel; Patient Compliance; Propensity Score; Radiotherapy, Conformal; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Survival Rate | 2017 |
Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Brain Neoplasms; Cranial Irradiation; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Response Evaluation Criteria in Solid Tumors; Treatment Outcome; Tumor Burden | 2018 |
Cytoplasmic YAP expression is associated with prolonged survival in patients with lung adenocarcinomas and epidermal growth factor receptor tyrosine kinase inhibitor treatment.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Cytoplasm; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Mutation; Phosphoproteins; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Response Evaluation Criteria in Solid Tumors; Survival Rate; Transcription Factors; YAP-Signaling Proteins; Young Adult | 2014 |
TLG-S criteria are superior to both EORTC and PERCIST for predicting outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Outcome Assessment, Health Care; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Response Evaluation Criteria in Solid Tumors; Sensitivity and Specificity; Survival Rate; Treatment Outcome | 2016 |
Optimal tumor shrinkage predicts long-term outcome in advanced nonsmall cell lung cancer (NSCLC) treated with target therapy: Result from 3 clinical trials of advanced NSCLC by 1 institution.
Topics: Academic Medical Centers; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; China; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Invasiveness; Neoplasm Staging; Predictive Value of Tests; Quinazolines; Response Evaluation Criteria in Solid Tumors; ROC Curve; Survival Analysis; Time Factors; Treatment Outcome | 2016 |